Gujarat Kidney and Super Speciality Limited submitted its Q2 FY27 investor presentation to BSE and NSE under Regulation 30 of SEBI Listing Regulations. The presentation discloses unaudited consolidated financial results for the quarter and half year ended 30 September 2026, which have undergone limited review by the statutory auditor.

Financial Performance - Q2 FY27

  • Revenue from operations: ₹3,809 lakhs, increased 11.1% quarter-on-quarter (QoQ) and 194.6% year-on-year (YoY)
  • Other income: ₹59 lakhs, decreased 14.8% QoQ but increased 567.5% YoY
  • Total income: ₹3,868 lakhs, increased 10.6% QoQ and 197.1% YoY
  • Gross profit: ₹3,334 lakhs with gross profit margin of 87.5%, improved 18 basis points QoQ but declined 242 basis points YoY
  • Employee cost: ₹777 lakhs, increased 47.0% QoQ and 249.0% YoY, reflecting investment in clinical talent
  • Other expenses: ₹1,535 lakhs, decreased 5.7% QoQ but increased 258.8% YoY
  • EBITDA: ₹1,022 lakhs with 26.8% margin, expanded 239 basis points QoQ but declined 1,281 basis points YoY
  • PAT: ₹660 lakhs with 17.3% margin, increased 24.0% QoQ and 129.4% YoY

Financial Performance - H1 FY27

  • Revenue from operations: ₹7,238 lakhs, increased 156.8% YoY (88% of FY26 full-year revenue)
  • Total comprehensive income: ₹1,203 lakhs, increased 44.6% YoY
  • Total comprehensive income attributable to owners: ₹1,115 lakhs, increased 47.6% YoY
  • Total comprehensive income attributable to non-controlling interests: ₹88 lakhs, increased 15.1% YoY

Balance Sheet Position (as of 30-Sep-26)

  • Equity share capital: ₹1,577 lakhs (unchanged from Mar-26)
  • Other equity: ₹24,787 lakhs (increased from ₹23,674 lakhs at Mar-26)
  • Total equity: ₹26,364 lakhs
  • Non-controlling interests: ₹623 lakhs (increased from ₹222 lakhs at Mar-26)
  • Net cash position: ₹1,488 lakhs (cash & bank ₹3,218 lakhs vs borrowings ₹1,729 lakhs, excluding leases)
  • Goodwill: ₹10,742 lakhs (increased from ₹9,073 lakhs at Mar-26)
  • Property, plant and equipment: ₹3,193 lakhs
  • Right of use assets: ₹1,010 lakhs

Operational Metrics

  • H1 FY27: 11,040 IPD admissions and 78,643 OPD visits (83% and 82% of FY26 full-year volumes respectively)
  • Bed occupancy: steady at ~55%
  • Average length of stay: ~6 days
  • Operating cash flow: positive at ₹42 lakhs in H1 FY27 vs negative ₹(736) lakhs in H1 FY26
  • PP&E investment: ₹623 lakhs in H1 FY27

Strategic Highlights

  • Inorganic expansion: ₹1,669 lakhs deployed towards acquisitions in H1 FY27
  • Dubai expansion: Acquired 51% stake in Dubai polyclinic (remaining 49% in process of acquisition) with revenue of 5.1 million AED for Jan'26-June'26
  • Asset-light business model: Operating through mix of leased and controlled facilities across central Gujarat
  • Hospital network: Includes 100% owned Parekh Hospital (Ahmedabad), Ashwini Medical Centre (Anand), Gujarat Kidney & Superspeciality Hospital (Vadodara), Gujarat Multispeciality Hospital (Godhra); 90% owned Surya Hospital (Borsad) and Gujarat Surgical Hospital (Vadodara); 51% owned Raj Palmland Hospital (Bharuch), Patel Multispeciality Hospital (Ankleshwar), and Dubai entity

Clinical Specializations

  • Pre-eminence in renal sciences with established sub-superspecialities in urology
  • Strong expertise in laparoscopic and minimally invasive surgeries
  • Expanded specialities include cardiology, oncology, orthopedics, gynecology, neuro-surgery
  • Performed first renal transplant and angiography at Godhra Hospital

Management Team

  • Dr. Pragnesh Yashwantsinh Bharpoda - Chairman and Managing Director, qualified urologist and surgeon
  • Dr. Bhartiben Pragnesh Bharpoda - Whole-time Director, qualified physiotherapist
  • Jagdishbhai Vinodchandra Thakkar - Non-Executive Director, hospital pharmacy operations
  • Independent Directors: Chartered Accountant/SEBI-registered Research Analyst, Pathologist, Ophthalmologist

The company has submitted Draft Red Herring Prospectus to BSE and NSE and is contemplating a potential offering subject to necessary approvals.